definiens: shall mean ( a ) fifty percent ( 50 % ) of the total DevelopmentCosts for IO Licensed Products for which [COMPANY] is the Post - POC Principal Party ( including, forthe avoidance of doubt, such Development Costs for any Special Termination Product that is anIO Antibody until the time such Special Termination Product becomes an Special TerminationProduct ) to the extent ( i ) directly attributable to the conduct of clinical trials of such IO LicensedProduct ( or Special Termination Product ), ( ii ) incurred from and after the date that such IOLicensed Product ( or Special Termination Product ) first became an IO Licensed Product underthis Agreement in accordance with the terms of the IO Discovery Agreement, and ( iii ) consistentwith the Global Development Budget in respect of such IO Licensed Product ( or SpecialTermination Product ), ( b ) [ * * * ] of the total Program Costs attributable to clinical development of IODiscovery Program Antibodies under the IO Discovery Program, solely to the extent that Sanofimade an IO or IO Reimbursement Payment in respect of such Program Costspursuant to Section 4.2 of the IO Discovery Agreement, and solely to the extent that Section 4.3of the IO Discovery Agreement expressly provides that such Program Costs are to be added tothe IO Development Balance, ( c ) [ * * * ] of the development costs incurred by Regeneron withrespect to any Non - IO Indication for an IO Licensed Product, solely to the extent that Sanofireimburses Regeneron for [ * * * ] of such development costs pursuant to Section 9.2(c ), and ( d ) [ * * * ] of the Additional Trial Costs incurred by Regeneron as a Post - POC Other Party, solely to theextent that [COMPANY] reimburses Regeneron for [ * * * ] of such Additional Trial Costs pursuant toSection 9.2(d )